GlassScriptPhysician profile
Magan B Parker
NPI 1932692282
$2,987.98
in general payments reported to CMS, 2019-2025
34 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $310 · 2023: $595 · 2024: $676 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,949.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $410.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $223.23 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $210.06 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $200.10 | 2021-2024 | Verquvo, Belsomra |
| Pfizer INC. | $176.17 | 2021-2025 | |
| Lilly USA, LLC | $167.40 | 2022-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $150.83 | 2023-2025 | |
| Amarin Pharma, INC. | $139.58 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.53 | 2021-2023 | Jardiance |
| Amgen INC. | $113.90 | 2021-2025 | Repatha, Repatha |
| Neurocrine Biosciences, INC. | $104.48 | 2024-2025 | Ingrezza |
| Abbvie INC. | $97.37 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $94.20 | 2021-2025 | Farxiga |
| Dexcom, INC. | $88.17 | 2022-2023 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $87.53 | 2024-2025 | Qutenza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $73.23 | 2025 | Cds - Mct/Cem Monitoring |
| Exact Sciences Corporation | $62.49 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $53.21 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $50.30 | 2025 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $44.35 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $41.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.06 | 2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $27.96 | 2024 | Trintellix |
| Lundbeck LLC | $27.13 | 2025 | Rexulti |
| Corium, LLC | $23.42 | 2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $22.21 | 2021 | |
| Esperion Therapeutics, INC. | $18.90 | 2025 | Nexletol |
| Chiesi USA, INC. | $18.90 | 2021 | |
| Eisai INC. | $17.69 | 2024 | |
| Medtronic, INC. | $17.54 | 2023 | Micra |
| Novo Nordisk INC | $16.32 | 2024 | Rybelsus |
| Sanofi-Aventis U.S. LLC | $16.21 | 2021 | |
| Seqirus USA INC | $14.52 | 2025 | Flucelvax |
| Idorsia Pharmaceuticals US INC | $14.17 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magan Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.